Iomed (Acquired)

Noninvasive, site-specific drug delivery technology to deliver compounds to the posterior segments of the eye

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Iomed (Acquired) plus 5403 other startups.